FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280587652> ?p ?o ?g. }

• W4280587652 abstract "Abstract Drug repurposing is a novel strategy for the development of new therapies against antibiotic-resistant bacteria. Zidovudine, an antiviral largely used in the HIV-therapy, exerts antibacterial activity against Gram-negative bacteria. Zidovudine was identified in a previous drug repurposing synergy screening as fosfomycin enhancer against Klebsiella pneumoniae ATCC 13883. Our aim was to evaluate the antibacterial in vitro activity of zidovudine-based combinations with last-line antibiotics against MDR/XDR K. pneumoniae isolates. We validated the zidovudine/fosfomycin combination against a collection of 12 MDR K. pneumoniae isolates by the checkerboard assay (CBA). In addition, we performed time-kill assays (TKA) to analyze synergistic and bactericidal activities of zidovudine paired combinations with fosfomycin, ceftazidime-avibactam, colistin and tigecycline. These were compared with frequent clinical combinations in the treatment of MDR Enterobacteriaceae. The potential of the triple zidovudine/fosfomycin/colistin was also assessed by TKA. CBA synergy confirmation rate between zidovudine/fosfomycin was 83.33%. TKA yielded synergy confirmation rates of 83.3% for zidovudine/ceftazidime-avibactam, 75% for zidovudine/fosfomycin, 75% for zidovudine/colistin and 66.6% for zidovudine/tigecycline with potent killing activities. Frequent clinical combinations displayed synergy rates of 41.6% for meropenem/ertapenem, 33.33% for meropenem/colistin, 75% for fosfomycin/colistin and 66.6% for fosfomycin/tigecycline with lower bactericidal efficacy than zidovudine-based combinations. The triple zidovudine/fosfomycin/colistin combination exhibited activities similar to fosfomycin/colistin and fosfomycin/zidovudine. As conclusion, zidovudine is an effective partner in in vitro combinations with existing antibiotics against MDR K. pneumoniae , especially with ceftazidime-avibactam, fosfomycin or colistin. Further studies are needed to elucidate the clinical potential of zidovudine as a repurposed drug in the antibacterial therapy." @default.
• W4280587652 created "2022-05-22" @default.
• W4280587652 creator A5009896455 @default.
• W4280587652 creator A5009926080 @default.
• W4280587652 creator A5072898321 @default.
• W4280587652 creator A5080965664 @default.
• W4280587652 creator A5089429945 @default.
• W4280587652 date "2022-05-17" @default.
• W4280587652 modified "2023-10-01" @default.
• W4280587652 title "Zidovudine multi-combos with last-line fosfomycin, ceftazidime-avibactam, colistin and tigecycline against Multi-Drug Resistant <i>Klebsiella pneumoniae</i>" @default.
• W4280587652 cites W1988049665 @default.
• W4280587652 cites W2007273156 @default.
• W4280587652 cites W2016562927 @default.
• W4280587652 cites W2030488466 @default.
• W4280587652 cites W2039994228 @default.
• W4280587652 cites W2053765655 @default.
• W4280587652 cites W2055500580 @default.
• W4280587652 cites W2072361904 @default.
• W4280587652 cites W2100266438 @default.
• W4280587652 cites W2106918243 @default.
• W4280587652 cites W2135640422 @default.
• W4280587652 cites W2142343447 @default.
• W4280587652 cites W2144785918 @default.
• W4280587652 cites W2399140686 @default.
• W4280587652 cites W2419220498 @default.
• W4280587652 cites W2517923973 @default.
• W4280587652 cites W2527579883 @default.
• W4280587652 cites W2606653806 @default.
• W4280587652 cites W2761407316 @default.
• W4280587652 cites W2769600019 @default.
• W4280587652 cites W2773186473 @default.
• W4280587652 cites W2801851274 @default.
• W4280587652 cites W2883732289 @default.
• W4280587652 cites W2888453829 @default.
• W4280587652 cites W2889290274 @default.
• W4280587652 cites W2896002881 @default.
• W4280587652 cites W2918973724 @default.
• W4280587652 cites W2951458531 @default.
• W4280587652 cites W2985198069 @default.
• W4280587652 cites W3008901682 @default.
• W4280587652 cites W3009021319 @default.
• W4280587652 cites W3048457837 @default.
• W4280587652 cites W3163720245 @default.
• W4280587652 cites W4210985946 @default.
• W4280587652 cites W4229924182 @default.
• W4280587652 cites W4233731022 @default.
• W4280587652 cites W4238344180 @default.
• W4280587652 doi "https://doi.org/10.1101/2022.05.17.492182" @default.
• W4280587652 hasPublicationYear "2022" @default.
• W4280587652 type Work @default.
• W4280587652 citedByCount "0" @default.
• W4280587652 crossrefType "posted-content" @default.
• W4280587652 hasAuthorship W4280587652A5009896455 @default.
• W4280587652 hasAuthorship W4280587652A5009926080 @default.
• W4280587652 hasAuthorship W4280587652A5072898321 @default.
• W4280587652 hasAuthorship W4280587652A5080965664 @default.
• W4280587652 hasAuthorship W4280587652A5089429945 @default.
• W4280587652 hasBestOaLocation W42805876521 @default.
• W4280587652 hasConcept C104317684 @default.
• W4280587652 hasConcept C159047783 @default.
• W4280587652 hasConcept C2776315533 @default.
• W4280587652 hasConcept C2777027569 @default.
• W4280587652 hasConcept C2777058267 @default.
• W4280587652 hasConcept C2777637488 @default.
• W4280587652 hasConcept C2778897966 @default.
• W4280587652 hasConcept C2779259085 @default.
• W4280587652 hasConcept C2779375183 @default.
• W4280587652 hasConcept C2780216070 @default.
• W4280587652 hasConcept C2780727368 @default.
• W4280587652 hasConcept C3013748606 @default.
• W4280587652 hasConcept C501593827 @default.
• W4280587652 hasConcept C523546767 @default.
• W4280587652 hasConcept C54355233 @default.
• W4280587652 hasConcept C547475151 @default.
• W4280587652 hasConcept C55493867 @default.
• W4280587652 hasConcept C71924100 @default.
• W4280587652 hasConcept C86803240 @default.
• W4280587652 hasConcept C89423630 @default.
• W4280587652 hasConcept C94665300 @default.
• W4280587652 hasConcept C98274493 @default.
• W4280587652 hasConceptScore W4280587652C104317684 @default.
• W4280587652 hasConceptScore W4280587652C159047783 @default.
• W4280587652 hasConceptScore W4280587652C2776315533 @default.
• W4280587652 hasConceptScore W4280587652C2777027569 @default.
• W4280587652 hasConceptScore W4280587652C2777058267 @default.
• W4280587652 hasConceptScore W4280587652C2777637488 @default.
• W4280587652 hasConceptScore W4280587652C2778897966 @default.
• W4280587652 hasConceptScore W4280587652C2779259085 @default.
• W4280587652 hasConceptScore W4280587652C2779375183 @default.
• W4280587652 hasConceptScore W4280587652C2780216070 @default.
• W4280587652 hasConceptScore W4280587652C2780727368 @default.
• W4280587652 hasConceptScore W4280587652C3013748606 @default.
• W4280587652 hasConceptScore W4280587652C501593827 @default.
• W4280587652 hasConceptScore W4280587652C523546767 @default.
• W4280587652 hasConceptScore W4280587652C54355233 @default.
• W4280587652 hasConceptScore W4280587652C547475151 @default.
• W4280587652 hasConceptScore W4280587652C55493867 @default.
• W4280587652 hasConceptScore W4280587652C71924100 @default.
• W4280587652 hasConceptScore W4280587652C86803240 @default.
• W4280587652 hasConceptScore W4280587652C89423630 @default.

• next